Eledon Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $280.4M
- Price
- $3.45
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.99%
- Volume
- 743.9K
About
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Quick stats
Shares outstanding81.3M
Computed float77.2M
Float / shares95.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001404281
Websitehttps://eledon.com
AI Summary
AI-generated1/15
majorbullishearnings
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals cleared a key regulatory hurdle with a successful FDA End-of-Phase 2 meeting, positioning tegoprubart to initiate a global Phase 3 kidney transplant trial in late 2026.
New data from the BESTOW trial showed tegoprubart maintained statistically significant kidney function superiority over tacrolimus at 18 months, while a separate study demonstrated 100% insulin independence in islet cell transplant patients.
Financially, the company holds $88.8 million in cash and investments, sufficient to fund operations into the second quarter of 2027, with a Q2 net loss of $31.6 million driven largely by non-cash warrant valuation changes.